Hong Kong Stock Movement
REMEGEN fell 10.75%. Based on recent key news:
<ol>
<li>
On December 8, the success rate of national medical insurance negotiations reached a historic high, and the commercial insurance catalog is expected to become an important increment, with policies encouraging the development of innovative drugs. REMEGEN is viewed positively; however, market support for innovative drugs has not been immediately reflected in stock prices, leading to a decline. Source: Zhitong Finance
</li>
<li>
On December 5, China International Capital Corporation pointed out that the proportion of domestic capital holding pharmaceutical stocks through the Hong Kong Stock Connect has decreased, and foreign capital holdings have also retreated. Although the direction of innovative drug layout remains unchanged, domestic capital tends to take profits, affecting REMEGEN's stock price. Source: Jinwu Finance
</li>
<li>
On December 5, China International Capital Corporation stated that the industry still has sufficient catalysts, including the announcement of medical insurance negotiation results, and investment sentiment in the sector is expected to stabilize and rise. However, short-term market sentiment fluctuations affect stock prices. Source: Jinwu Finance. Policy support for the innovative drug industry, but risks remain.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Innovent Biologics fell 6.79%. Based on recent key news:
<ol>
<li>
On December 8, Innovent Biologics announced that its seven innovative products were successfully included in the new national medical insurance catalog, covering areas such as oncology and cardiovascular diseases, improving patient access to medications. This news did not boost the stock price; instead, it fell due to market expectations for sales after the implementation of medical insurance policies being lower than anticipated. Source: Zhitong Finance
</li>
<li>
On December 5, Innovent Biologics reached a global strategic cooperation with Takeda Pharmaceutical, completing a share issuance agreement involving approximately HKD 778 million. Although the cooperation is seen as a long-term benefit, the market remains cautious about the actual benefits of the cooperation in the short term, and the stock price has not broken through previous highs. Source: Caihua News
</li>
<li>
On December 8, there were multiple large transactions in front of Innovent Biologics, involving approximately 13.0734 million shares at an average price of HKD 92, with a total value exceeding HKD 1.2 billion. Large transactions are often seen as pressure on stock prices, leading to further declines. Source: Zhitong Finance. Significant impact of policy changes in the pharmaceutical industry.
</li>
</ol>
Kangfang Biotech rose 0.16%. Based on recent key news:
<ol>
<li>
On December 7, Kangfang Biotech announced that its five newly launched drugs were successfully included in the 2025 version of the national medical insurance drug catalog. This move will enhance the market accessibility and sales potential of the drugs, driving up the stock price. Source: Zhitong Finance
</li>
<li>
On December 8, Economic Information Daily reported that Kangfang Biotech's five new drugs were included in the latest national medical insurance catalog, further confirming the company's success in medical insurance negotiations and boosting market confidence. Source: Economic Information Daily
</li>
<li>
On December 7, Kangfang Biotech's announcement showed that all self-developed new drugs' indications successfully entered the national medical insurance catalog, which is expected to have a positive impact on the company's future performance. Source: Huigang Communications. Favorable policies for the biopharmaceutical industry, with significant capital inflow.
</li>
</ol>
BeiGene fell 2.68%. Based on recent key news:
<ol>
<li>On December 8, the National Healthcare Security Administration released a new version of the drug catalog, and two of BeiGene's drugs entered the commercial insurance innovative drug catalog, attracting market attention. The new catalog will be implemented on January 1, 2026, and the implementation of the commercial insurance innovative drug catalog is expected to open up broader market space for innovative drugs
Source: Zhitong Finance</li>
</ol>
On December 8, Jiangyin International's research report pointed out that the pharmaceutical industry is experiencing a critical turning point, with continuous attention on innovative drug layouts. BeiGene is recommended as a target with rich short-term catalysts, and its valuation still does not reflect the value of its core blockbuster products. Source: Zhitong Finance
On December 8, a report from Daiwa Capital Markets analysts stated that BeiGene's cancer therapy Brukinsa may continue to boost global sales in the coming years, with the company expected to achieve positive profits and positive free cash flow. Source: Daiwa Capital Markets, the innovative drug layout in the pharmaceutical industry is receiving attention, and capital flows are evident.
Stocks ranked at the top of the industry by market capitalization
Kanglongda Biotech-B fell 3.22%. Based on recent key news:
On December 5, Kanglongda Biotech established a strategic partnership with Crescent Biopharma to jointly develop cancer treatment methods. This cooperation involves an upfront payment of $80 million and milestone payments of up to $1.25 billion, driving stock price fluctuations.
On December 5, Kanglongda Biotech's innovative drug R&amp;D faces multiple uncertainties, especially the R&amp;D risks and funding pressures of SKB105 and CR-001, affecting market confidence.
On December 5, Bernstein gave Kanglongda Biotech an &#34;Outperform&#34; rating, with a target price of HKD 545, expecting the company's revenue to grow rapidly in the coming years, enhancing market expectations. Competition in the innovative drug field is intensifying, and funding pressure is significant

09995

REMEGEN fell 10.75%; Innovent Biologics fell 6.79%, with a transaction volume of HKD 3.978 billion; CanSino Biologics rose 0.16%, with a transaction volume of HKD 642 million; BeiGene fell 2.68%, with a transaction volume of HKD 585 million; Kelun-Biotech fell 3.22%, with a market capitalization of HKD 103.8 billion

HK Stock Movers Tracker

REMEGEN

Hong Kong stock movement: The positive impact of medical insurance negotiations cannot stop the decline in stock prices, REMEGEN suffers a heavy sell-off from both domestic and foreign investors, plunging 10.75%